Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519661 · ClinicalTrials.gov registry record · Phase 4
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 157
- Enrollment target
NCT01519661 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 157 participants.
The verdict
NCT01519661, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 157 participants
- Enrollment target
Study Summary
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
Interventions
- DRUG TBM100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519661
The ClinicalTrials.gov registry entry for NCT01519661 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TBM100 is the first listed.
NCT01519661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01519661 about?
NCT01519661 is a clinical study titled "Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis". This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
What is the current status of trial NCT01519661?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 157 participants. The study started on 2012-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01519661?
The interventions under investigation include: TBM100 (DRUG).
Who is sponsoring clinical trial NCT01519661?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.